about
Mrvi1, a common MRV integration site in BXH2 myeloid leukemias, encodes a protein with homology to a lymphoid-restricted membrane protein Jaw1Comparison of a restrictive versus liberal red cell transfusion policy for patients with myelodysplasia, aplastic anaemia, and other congenital bone marrow failure disordersAlternative agents versus prophylactic platelet transfusion for preventing bleeding in patients with thrombocytopenia due to chronic bone marrow failure: a network meta-analysis and systematic reviewComparison of a restrictive versus liberal red cell transfusion policy for patients with myelodysplasia, aplastic anaemia, and other congenital bone marrow failure disordersSelective impairment of platelet activation to collagen in the absence of GATA1GATA-1 forms distinct activating and repressive complexes in erythroid cellsStructure of the human 3-methyladenine DNA glycosylase gene and localization close to the 16p telomereMinimizing risk of hypomethylating agent failure in patients with higher-risk MDS and practical management recommendationsStructure of the leukemia oncogene LMO2: implications for the assembly of a hematopoietic transcription factor complexStructural Basis for LMO2-Driven Recruitment of the SCL:E47bHLH Heterodimer to Hematopoietic-Specific Transcriptional TargetsSomatic SF3B1 mutation in myelodysplasia with ring sideroblastsAssessment of Minimal Residual Disease in Standard-Risk AML.Transient Abnormal Myelopoiesis and AML in Down Syndrome: an UpdateReprint of: Allogeneic hematopoietic cell transplantation for acute myeloid leukemiaRecent insights into the mechanisms of myeloid leukemogenesis in Down syndromeDifferential use of SCL/TAL-1 DNA-binding domain in developmental hematopoiesisHaploinsufficiency of GATA-2 perturbs adult hematopoietic stem-cell homeostasisInositol polyphosphate 4-phosphatase type I regulates cell growth downstream of transcription factor GATA-1Decoding hematopoietic specificity in the helix-loop-helix domain of the transcription factor SCL/Tal-1Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndromes.Characterization of megakaryocyte GATA1-interacting proteins: the corepressor ETO2 and GATA1 interact to regulate terminal megakaryocyte maturationMeasurement of utility values in the UK for health states related to immune thrombocytopenic purpura.SCL-mediated regulation of the cell-cycle regulator p21 is critical for murine megakaryopoiesis.c-Myb and GATA-1 alternate dominant roles during megakaryocyte differentiation.Alternative agents to prophylactic platelet transfusion for preventing bleeding in people with thrombocytopenia due to chronic bone marrow failure: a meta-analysis and systematic reviewClonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia.GATA1s induces hyperproliferation of eosinophil precursors in Down syndrome transient leukemia.The U2AF1S34F mutation induces lineage-specific splicing alterations in myelodysplastic syndromes.Factors predicting long-term survival after T-cell depleted reduced intensity allogeneic stem cell transplantation for acute myeloid leukemia.Generation of bivalent chromatin domains during cell fate decisionsLineage-specific combinatorial action of enhancers regulates mouse erythroid Gata1 expressionGATA1-mediated megakaryocyte differentiation and growth control can be uncoupled and mapped to different domains in GATA1Identification of distinct molecular phenotypes in acute megakaryoblastic leukemia by gene expression profiling.Origins and functional consequences of somatic mitochondrial DNA mutations in human cancerPrognostic value of monitoring a candidate immunophenotypic leukaemic stem/progenitor cell population in patients allografted for acute myeloid leukaemia.Development of real-time quantitative polymerase chain reaction assays to track treatment response in retinoid resistant acute promyelocytic leukemia.Multicenter validation of a reproducible flow cytometric score for the diagnosis of low-grade myelodysplastic syndromes: results of a European LeukemiaNET studyNormal Hematopoietic Progenitor Subsets Have Distinct Reactive Oxygen Species, BCL2 and Cell-Cycle Profiles That Are Decoupled from Maturation in Acute Myeloid LeukemiaFactors influencing success of clinical genome sequencing across a broad spectrum of disordersPerturbation of fetal liver hematopoietic stem and progenitor cell development by trisomy 21
P50
Q22010014-BDFDD5A3-6B59-417D-AB8C-1BDD97C32B1BQ24186615-DB853BD7-0987-4AFE-8149-BEFC396A9820Q24186703-5B18984C-E3B8-4B91-8E86-478FE6D6AA46Q24187692-8C46DCD4-B8A3-4B2E-9E5C-7C373A35671EQ24294468-61A0F076-82EA-4188-AB31-389CBFA5900BQ24303958-CDAF47EC-BB0D-4C31-A56A-101FC08F05D3Q24563138-7AD913CC-910D-409E-BB2C-04912E35C166Q26865362-21455BC0-CA74-433E-BBE9-C6654682976CQ27665882-D151A18A-03EB-4D59-B7EA-A3DDCD988A08Q27678941-558D8343-EB22-4899-9668-A6B23C9A377BQ27851675-9898024C-0F61-4195-BEFC-B1BE166C7E91Q27853325-C90D7B5B-A6C5-47A6-8423-8288ADCB6285Q28079980-ADB152B8-FE71-4864-A87F-2428E6FF59E4Q28083485-0B431B14-928A-415B-81F6-C1833736B02EQ28205161-1884DE94-30CB-499B-8924-D3CDF8BF6C33Q28586409-01C0EE53-F97B-4F32-81FA-557409DFA377Q28587266-88FD0839-B21F-4607-8BC5-857262135F46Q28592644-B332EDD7-6689-4706-A94A-7BA017500CD0Q28594728-1A84BCAD-71BF-4B6E-93E3-286FE7A6BB5FQ30883788-EBCD2EC7-96C4-475A-B198-6F3F3D224E38Q33380348-B782EA8A-56DD-430B-BF98-AE45E2F0A228Q33390163-C8892E0C-6D9B-43A5-A1AB-A1C7D193D8F3Q33395408-93104F94-DEDC-4F9E-9E68-BB4234C14229Q33395761-115531BF-E249-4A97-929E-6C6443DB1E43Q33436416-1EE78DA9-54A7-49AB-BAE0-4EE116B403E9Q33711497-CC36226C-6AC8-4E55-9656-7E90F96C3547Q33717768-5E458F6B-F876-4AB5-80A8-3C70324609AAQ33746465-AEA340E8-FAB7-4286-BAF1-32ECB0E42D1FQ33886217-0A7E6C23-AE53-4CCD-A4F8-1B25D4922CF0Q34027198-B80DF605-03EA-4D88-9C9D-A42D90D3E479Q34052719-FD9FC298-899B-47CC-BC64-4C3D485C4A93Q34097148-911C4B6B-6CFE-42F2-B0E3-2CDB23BCC964Q34480244-64C32A17-F968-4079-B572-BC660B122F0BQ35212322-883A3FEA-4E67-4375-B31A-E556591874AEQ35348105-39183073-1B59-49A0-A2BE-A8F19C8285E1Q35971837-E2A3F889-34AD-47A5-9E6F-535152F5DCA6Q36133023-95B5D0F3-BC81-42E4-9C3A-318987212EEAQ36144842-655A32DC-FD08-4ADC-8A3E-39774A2C80E7Q36147983-AD20C168-C28C-4511-AD17-D99325D7FD20Q36378527-8EC9B0E2-AA74-46FB-8AEA-09E645AD66DA
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Paresh Vyas
@ast
Paresh Vyas
@en
Paresh Vyas
@es
Paresh Vyas
@nl
Paresh Vyas
@sl
type
label
Paresh Vyas
@ast
Paresh Vyas
@en
Paresh Vyas
@es
Paresh Vyas
@nl
Paresh Vyas
@sl
prefLabel
Paresh Vyas
@ast
Paresh Vyas
@en
Paresh Vyas
@es
Paresh Vyas
@nl
Paresh Vyas
@sl
P1053
B-5708-2009
P106
P1153
57194441630
P31
P3829
P496
0000-0003-3931-0914
P569
2000-01-01T00:00:00Z